HSP90AB1 and glioblastoma: Therefore, HSP90 inhibitors like 17-AAG may have therapeutic potential in GBM, either as a single therapeutic strategy or in combination with other treatments [36,88] and should be considered for patients whose tumors remain refractory to most current treatments.